港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

恆瑞醫藥

65.500

+0.0500.08%

成交量：147.52萬

成交額：9,707.26萬

市值：4,347.24億

市盈率：57.47

高：66.500

開：65.450

低：65.300

收：65.450

52周最高：95.200

52周最低：52.500

股本：66.37億

香港流通股本：2.58億

量比：0.89

換手率：0.57%

股息：- -

股息率：- -

每股收益(LYR):1.140

淨資產收益率：14.34%

總資產收益率：8.37%

市淨率：6.41

市盈率(LYR):57.47

市銷率: 12.31

資料載入中...

總覽公司新聞資訊公告

標普全球市場財智列出近期十大沽空比例最高港股

阿斯达克财经

港股公告掘金 | 螞蟻集團收購耀才證券金融的要約已獲批准 3月17日復牌

恒瑞醫藥(600276.SH)：SHR-1819注射液聯合SHR-1905注射液用於治療特應性皮炎獲批開展臨床試驗

恒瑞醫藥：富馬酸立康可泮膠囊的藥品上市許可申請獲受理

恒瑞醫藥獲Wellington Management Group LLP增持4.96萬股

Wellington Management Group LLP增持恒瑞醫藥(01276)4.96萬股每股作價約66.13港元

恒瑞醫藥(600276.SH)：1類創新藥海曲泊帕乙醇胺片新增適應症

恒瑞醫藥：鹽酸伊立替康脂質體注射液（Ⅱ）臨床試驗獲批

恒瑞醫藥：舒地胰島素諾利糖肽注射液上市許可申請獲國家藥監局受理

每日经济新闻

創新賽道升温，恒瑞、百濟等藥企集體加碼研發

世界腎臟日：全球219款腎病藥上市！金賽藥業BCMA新藥與恒瑞醫藥SGLT2/GLP-1管線競速

「十五五」開局，恒瑞醫藥將站在新起點加速推進醫藥創新

世界腎臟日｜警惕「沉默殺手」，藥企競速「護腎」

21世纪经济报道

14億歐元BD終止！恒瑞被默克"退貨"的背後……

穩字當頭：恒瑞醫藥換屆稍欠鋭氣

馮佶，恒瑞醫藥女總裁榮登2026「福布斯中國傑出商界女性100」排行榜

北京药研汇

今日，康寧傑瑞官宣新CTO！來自恒瑞

恒瑞醫藥海外大單告吹

股市动态分析

恒瑞醫藥：注射用SHR-9803獲臨床試驗批准

南方财经网

恒瑞醫藥：董事會會議通告

香港交易所

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/01276/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":65.5,"timestamp":1773821285004,"preClose":65.45,"halted":0,"volume":1475200,"delay":0,"changeRate":0.0007639419404124852,"floatShares":258000000,"shares":6637000000,"eps":1.1398123397950946,"marketStatus":"已收盤","change":0.05,"latestTime":"03-18 16:08:05","open":65.45,"high":66.5,"low":65.3,"amount":97072600,"amplitude":0.018335,"askPrice":65.9,"askSize":7800,"bidPrice":65.5,"bidSize":5200,"shortable":3,"etf":0,"ttmEps":1.3224193951289869,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1773883800000},"marketStatusCode":5,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":65.45,"openAndCloseTimeList":[[1773797400000,1773806400000],[1773810000000,1773820800000]],"volumeRatio":0.892426,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恆瑞醫藥","latestPrice":56.88,"timestamp":1773817200000,"preClose":56.3,"halted":0,"volume":39379300,"delay":0,"premium":"+1.03"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"8.37%","roe":"14.34%","lyrEps":1.139812,"volumeRatio":0.892426,"shares":6637000000,"dividePrice":0,"high":66.5,"amplitude":0.018335,"preClose":65.45,"low":65.3,"week52Low":52.5,"pbRate":"6.41","psRate":"12.31","week52High":95.2,"institutionHeld":0,"latestPrice":65.5,"committee":-0.2,"eps":1.1398123397950946,"divideRate":0,"volume":1475200,"delay":0,"ttmEps":1.3224193951289869,"open":65.45,"prevYearClose":71.25,"prevWeekClose":64,"prevMonthClose":66.5,"prevQuarterClose":71.25,"fiveDayClose":65.85,"twentyDayClose":70.25,"sixtyDayClose":70.85,"earningDate":1774454400000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2026-03-26","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null},{"date":"2025-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761615000000,"name":null,"time":"","dateTimestamp":1761580800000,"actualEps":null},{"date":"2025-08-21","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755739800000,"name":null,"time":"","dateTimestamp":1755705600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.6667,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1772208000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2026-03-17","current":50.029478,"percent":0.049261,"low":46.986716,"twenty":51.681209,"median":55.150445,"eighty":60.546267,"high":65.582363,"avg":55.867749,"sd":4.578757,"marketCap":424542868676.8},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91},{"date":"2025-10-17","current":58.903713,"twenty":52.323014,"median":59.170669,"eighty":62.619084,"marketCap":472537436949.31},{"date":"2025-10-24","current":59.187086,"twenty":52.484015,"median":59.039802,"eighty":62.52839,"marketCap":474983377696.11},{"date":"2025-10-31","current":57.072441,"twenty":52.552922,"median":59.021138,"eighty":62.417499,"marketCap":465758305542.93},{"date":"2025-11-07","current":54.713071,"twenty":52.619069,"median":58.881843,"eighty":62.304573,"marketCap":446224987036.64},{"date":"2025-11-14","current":55.883072,"twenty":52.812504,"median":58.231971,"eighty":62.27542,"marketCap":457058673340.29},{"date":"2025-11-21","current":52.805265,"twenty":52.880927,"median":57.030538,"eighty":62.209511,"marketCap":431684582485.14},{"date":"2025-11-28","current":55.237621,"twenty":52.99843,"median":56.630614,"eighty":62.069705,"marketCap":453209419829.34},{"date":"2025-12-05","current":54.841023,"twenty":53.00899,"median":56.437545,"eighty":61.965159,"marketCap":450729029423.46},{"date":"2025-12-12","current":56.212257,"twenty":53.045529,"median":56.385682,"eighty":61.891765,"marketCap":462853512587.19},{"date":"2025-12-19","current":54.083493,"twenty":53.045529,"median":56.227363,"eighty":61.831221,"marketCap":446374731108.34},{"date":"2025-12-24","current":54.414957,"twenty":53.090114,"median":56.103073,"eighty":61.798561,"marketCap":450509359276.9},{"date":"2026-01-02","current":53.078544,"twenty":53.065996,"median":55.972407,"eighty":61.785925,"marketCap":441174507319.22},{"date":"2026-01-09","current":56.743223,"twenty":53.0878,"median":56.0944,"eighty":61.695241,"marketCap":472808676524.34},{"date":"2026-01-16","current":55.187351,"twenty":53.304215,"median":56.103073,"eighty":61.405393,"marketCap":461338821289.95},{"date":"2026-01-23","current":52.546341,"twenty":53.0878,"median":56.076447,"eighty":61.296167,"marketCap":438839874056.97},{"date":"2026-01-30","current":51.677141,"twenty":52.994149,"median":55.908509,"eighty":61.278475,"marketCap":433553740508.2},{"date":"2026-02-06","current":50.918226,"twenty":52.680723,"median":55.839154,"eighty":61.101743,"marketCap":428270226283.58},{"date":"2026-02-13","current":51.771686,"twenty":52.512455,"median":55.711415,"eighty":60.890064,"marketCap":437949787160.49},{"date":"2026-02-20","current":51.752043,"twenty":52.351169,"median":55.691374,"eighty":60.824953,"marketCap":437153052005.04},{"date":"2026-02-27","current":50.215456,"twenty":52.151244,"median":55.507566,"eighty":60.720339,"marketCap":428825318404.97},{"date":"2026-03-06","current":49.335298,"twenty":51.80347,"median":55.280584,"eighty":60.654676,"marketCap":417912584744.19},{"date":"2026-03-13","current":48.90444,"twenty":51.75217,"median":55.201025,"eighty":60.572606,"marketCap":416170839186.33},{"date":"2026-03-17","current":49.957573,"twenty":51.681209,"median":55.150445,"eighty":60.546267,"marketCap":424542868676.8}],"updateTime":1773815217787},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620078416","title":"標普全球市場財智列出近期十大沽空比例最高港股","url":"https://stock-news.laohu8.com/highlight/detail?id=2620078416","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620078416?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 09:21","pubTimestamp":1773710460,"startTime":"0","endTime":"0","summary":"标普全球市场财智列出截至上周五在香港十大沽空比例最高港股。数据是根据来自标普全球市场财智的证券金融数据集计算得出。计算沽空的指标为借出股份占已发行股份总数的百分比。沽空资料截至 2026-03-16 16:25。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190627142633458_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190627142633458_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1509620/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1509620/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0607220059.USD","LU0650527681.SGD","HK0000306701.USD","LU1720050803.USD","LU0831093199.SGD","LU0918141705.HKD","LU1303224171.USD","LU2476274720.SGD","LU1282649810.SGD","LU1152091168.USD","LU0084288322.USD","LU0630378692.HKD","LU0293314216.USD","LU0762541174.USD","LU0348788117.USD","LU1046422090.SGD","LU1880383366.USD","LU0488056044.USD","LU0359201612.USD","SG9999002828.SGD","LU0314109678.HKD","002050","01072","09660","LU0106959298.USD","LU2476274308.USD","PAImain","PNGAY","01919","LU0819123356.HKD","LU0254981946.USD","BK1506","LU1282649141.HKD","LU1655091459.SGD","LU1224444064.USD","LU0149721374.USD","LU0862451753.SGD","LU0051755006.USD","LU0561508036.HKD","LU0181495838.USD","SG9999004220.SGD","LU0871576103.HKD","LU0880133367.SGD","LU0862451837.USD","BK1507","LU1048588211.SGD","LU0865486749.SGD","LU0163747925.USD","BK1526","LU0831103253.SGD","LU0640798160.USD","LU0856984785.SGD","BK1116","LU0328353924.USD","LU1719994722.HKD","SG9999002562.SGD","LU0791591158.USD","LU1481107354.HKD","HK0000320223.HKD","LU0348784397.USD","HK0000320264.USD","IE0008369823.USD","LU0823426480.USD","LU0823426308.USD","LU1044875133.USD","LU0463099449.HKD","LU1152091754.HKD","LU2348773727.SGD","BK1205","LU0210527791.USD","LU0348816934.USD","LU0348814723.USD","LU0651946864.USD","LU1515016050.SGD","LU0918141887.USD","LU0211977185.USD","LU2399975544.HKD","LU1235295612.USD","LU1820825898.SGD","SG9999000459.SGD","LU0348783233.USD","02768","IE00BGHQDM52.EUR","LU1051768304.USD","IE00BF5LJ272.USD","LU0384037296.USD","LU0441854154.USD","LU1769817096.USD","LU0348827113.USD","LU0594300179.USD","LU1146622755.USD","02050","LU0235996351.USD","LU1328277881.USD","LU1960683339.HKD","LU0165289439.USD","LU2348774022.SGD","LU0164865239.USD","LU0370786039.SGD","LU0196878994.USD","BK1183","LU0326950275.SGD","LU0588546209.SGD","IE00BYV24P56.USD","LU2226246903.HKD","LU0828237940.HKD","LU0315179316.USD","LU1880383440.USD","LU0106252389.USD","SG9999002463.SGD","LU0821914370.USD","LU1048596156.SGD","LU0117844026.USD","IE0003895053.USD","LU0675040207.SGD","LU0054450605.USD","IE00BMCWC346.EUR","LU0630378429.USD","BK1191","IE0034224299.USD","BK1607","IE00BZ08YT58.USD","02318","LU0348735423.USD","LU0039217434.USD","LU0449515922.USD","BK1522","IE00BZ08YS42.EUR","LU1961090484.USD","600875","IE00BVYPNP33.GBP","LU0327786744.USD","LU0828237510.HKD","LU0164872284.USD","LU2152927971.USD","BK1521","LU0878005551.USD","SG9999011746.SGD","LU0417516571.SGD","LU0359202008.SGD","01276","LU2424517915.HKD","LU1282651121.HKD","BK1529","BK1535","LU1807302812.USD","SG9999001903.USD","00763","002768","LU0634319403.HKD","BK1550","LU0048580855.USD","LU0882747503.HKD","LU0898667661.SGD","BK1184","LU0648948544.HKD","BK1589","LU0540923850.HKD","LU0149534421.HKD","LU0572944931.SGD","BK1103","02013","LU0791590937.USD","BK1546","BK1610","LU0651947912.USD","LU0049112450.USD","LU0594300419.USD","LU1282651048.USD","LU0043850808.USD","LU1642822792.SGD","LU0011963245.USD","IE00B29SXG58.USD","LU1794554557.SGD","BK1110","LU0049853897.USD","LU1044874839.SGD","LU0456827905.SGD","LU2153592121.USD","LU0067412154.USD","LU0501845795.SGD","BK1109","LU0708995583.HKD","LU1282648689.USD","LU0878004406.USD","BK1518","LU0762540952.USD","BK1505","LU0244354667.USD","LU1188198961.HKD","LU0890818403.SGD","LU0588545490.SGD","LU0417516738.SGD","601919","LU1769817179.HKD","LU2153591404.USD","300750","LU1251922891.USD","LU0228659784.USD","LU0588545730.USD","LU0784639295.USD","LU1981816686.USD","LU0359201885.HKD","000063","BK1516","BK1590","IE00B031HY20.USD","LU0197773160.USD","LU0315178854.USD","LU0531971595.HKD","HPAD.SI","LU0605514214.HKD","LU1008478684.HKD","LU1105468828.SGD","LU0348783662.USD","82318","LU1115378108.SGD","IE0008368742.USD","03145","BK1149","LU0348805143.USD","LU1366334578.USD","600276","LU1051769294.HKD","BK1240","IE0032431581.USD","HK0001040168.HKD","LU1282649067.USD","LU1813983027.USD","LU2039709279.SGD","IE00BVYPNQ40.USD","LU0348825331.USD","LU0052750758.USD","LU0164880469.USD","SG9999001440.SGD","LU2778985437.USD","03750","LU1993786604.SGD","LU0072913022.USD","LU1226287529.USD","LU1770034418.SGD","LU1044876610.USD","LU0140636845.USD","LU1211504680.USD","IE00BZ08YR35.GBP","LU0762542818.HKD","LU2293587155.HKD","SG9999014674.SGD","LU0588545904.SGD","LU0797268264.HKD","LU1831875114.USD","601318","LU1023057109.AUD","LU2543165471.USD","LU0228367735.SGD","LU0307460666.USD","LU1366334651.USD","LU0819121731.USD","LU0072462343.USD","HK0000306685.HKD","LU0197773673.USD","LU0417516902.SGD","LU0611395673.USD","LU0320764599.SGD"],"gpt_icon":1},{"id":"2620241656","title":"港股公告掘金 | 螞蟻集團收購耀才證券金融的要約已獲批准 3月17日復牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2620241656","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620241656?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 09:04","pubTimestamp":1773709477,"startTime":"0","endTime":"0","summary":"重大事项：恒瑞医药(01276)：SHR-1819注射液、SHR-1905注射液获得药物临床试验批准通知书复宏汉霖(02696)：PIMURUTAMAB HLX07联合汉斯状和化疗治疗晚期鳞状非小细胞肺癌的临床试验申请获国家药监局批准白云山(00874)：虚汗停颗粒用于儿童反复呼吸道感染的临床试验申请获批派格生物医药-B(02565)与腾瑞制药达成派达康中国大陆独家商业化合作 商业化目标累计销售规","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414674.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","06688","BK1521","LU0359202008.SGD","BK1515","HK0000320264.USD","02565","LU0359201885.HKD","HK0000306685.HKD","01276","HK0000320223.HKD","LU1023057109.AUD","LU0359201612.USD","BK1147","BK1161","VXUS","02696","00874","BK4588","BK1197","BK1606","HK0000165453.HKD","01428","HK0000306701.USD","BK1191","LU2543165471.USD"],"gpt_icon":1},{"id":"2619565624","title":"恒瑞醫藥(600276.SH)：SHR-1819注射液聯合SHR-1905注射液用於治療特應性皮炎獲批開展臨床試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2619565624","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619565624?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 17:17","pubTimestamp":1773652643,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司子公司广东恒瑞医药有限公司收到国家药品监督管理局(以下简称“国家药监局”)核准签发关于SHR-1819注射液、SHR-1905注射液的《药物临床试验批准通知书》。经审查，2025年12月18日受理的SHR-1819注射液、SHR-1905注射液符审批结论合药品注册的有关要求，同意开展临床试验。申请的适应症：SHR-1819注射液联合SHR-1905注射液用于治疗特应性皮炎。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828474.EUR","BK0028","BK0183","LU2097828714.EUR","LU2580892789.USD","LU0405327148.USD","BK0239","LU1023057109.AUD","LU1781817850.SGD","LU2097828557.USD","LU1064131003.USD","LU0359201612.USD","LU1969619763.USD","LU2097828805.USD","LU2148510915.USD","LU2580892862.HKD","LU1328615791.USD","LU1997244956.HKD","LU2097828631.EUR","01276","LU1997245094.SGD","BK1191","LU1064130708.USD","BK0060","LU1580142542.USD","LU2488822045.USD","LU1146622755.USD","LU2328871848.SGD","LU2543165471.USD","BK0196","LU1997245177.USD","LU1655091616.SGD","LU2495084118.USD","LU0359201885.HKD","BK0188","LU0405327494.USD","LU1820825898.SGD","BK0012","LU1255011170.USD","LU2289578879.USD","LU0359202008.SGD","600276"],"gpt_icon":0},{"id":"2619557654","title":"恒瑞醫藥：富馬酸立康可泮膠囊的藥品上市許可申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2619557654","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619557654?lang=zh_tw&edition=fundamental","pubTime":"2026-03-16 17:10","pubTimestamp":1773652230,"startTime":"0","endTime":"0","summary":"【恒瑞医药：富马酸立康可泮胶囊的药品上市许可申请获受理】恒瑞医药(600276)3月16日公告，近日，子公司成都盛迪医药有限公司收到国家药监局下发的受理通知书，富马酸立康可泮（HRS-5965）胶囊的药品上市许可申请获国家药监局受理。子公司广东恒瑞医药有限公司收到国家药监局核准签发关于SHR-1819注射液、SHR-1905注射液的药物临床试验批准通知书，将于近期开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603163673173239.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0060","LU1580142542.USD","BK0196","LU2097828805.USD","LU2097828474.EUR","BK1191","LU1997245177.USD","LU2097828631.EUR","LU2097828557.USD","BK0188","LU2097828714.EUR","LU1064130708.USD","BK0012","LU1969619763.USD","LU2488822045.USD","BK0183","LU1781817850.SGD","LU2289578879.USD","LU2543165471.USD","LU1328615791.USD","LU0405327148.USD","LU1064131003.USD","LU2580892862.HKD","LU1146622755.USD","LU1820825898.SGD","LU2580892789.USD","BK0028","LU2495084118.USD","600276","LU2328871848.SGD","LU2148510915.USD","LU0359201612.USD","LU0359201885.HKD","LU1023057109.AUD","LU1655091616.SGD","LU1997244956.HKD","BK0239","LU1255011170.USD","LU0359202008.SGD","LU0405327494.USD","01276","LU1997245094.SGD"],"gpt_icon":0},{"id":"2619170749","title":"恒瑞醫藥獲Wellington Management Group LLP增持4.96萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2619170749","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619170749?lang=zh_tw&edition=fundamental","pubTime":"2026-03-15 15:28","pubTimestamp":1773559680,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新数据显示，3月11日，Wellington Management Group LLP增持恒瑞医药（01276）4.96万股，每股作价66.1267港元，总金额约为327.99万港元。增持后最新持股数目约为2324.44万股，持股比例为9.00%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-15/doc-inhqzzfv9634355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","LU2488822045.USD","LU1328615791.USD","LU1997244956.HKD","LU0359201885.HKD","LU1997245094.SGD","01276","LU2328871848.SGD","LU1064131003.USD","BK0012","LU0405327494.USD","BK0196","LU0405327148.USD","LU0359201612.USD","LU1255011170.USD","LU2543165471.USD","LU2097828805.USD","LU2097828474.EUR","BK0239","LU2580892862.HKD","LU1781817850.SGD","LU1580142542.USD","LU1820825898.SGD","LU2097828631.EUR","BK0028","600276","LU1146622755.USD","LU2580892789.USD","BK0183","LU1969619763.USD","LU0359202008.SGD","LU2097828557.USD","LU2148510915.USD","LU1023057109.AUD","LU1997245177.USD","LU1655091616.SGD","LU2097828714.EUR","BK0060","LU2289578879.USD","LU1064130708.USD","BK0188","LU2495084118.USD"],"gpt_icon":0},{"id":"2619919761","title":"Wellington Management Group LLP增持恒瑞醫藥(01276)4.96萬股 每股作價約66.13港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619919761","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619919761?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 19:19","pubTimestamp":1773400763,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，3月11日，Wellington Management Group LLP增持恒瑞医药(01276)4.96万股，每股作价66.1267港元，总金额约为327.99万港元。增持后最新持股数目约为2324.44万股，持股比例为9.00%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828714.EUR","LU1064131003.USD","LU1580142542.USD","LU1064130708.USD","LU2097828631.EUR","LU1997244956.HKD","LU0405327148.USD","LU1820825898.SGD","LU2543165471.USD","BK0188","LU2488822045.USD","BK0196","LU1997245177.USD","BK0239","LU1969619763.USD","LU2097828474.EUR","LU1328615791.USD","LU2580892789.USD","600276","LU2097828805.USD","LU1781817850.SGD","01276","BK0012","LU0405327494.USD","BK1191","LU0359202008.SGD","LU1655091616.SGD","LU1023057109.AUD","LU1255011170.USD","BK0060","LU2580892862.HKD","LU1146622755.USD","LU0359201612.USD","LU2148510915.USD","LU2495084118.USD","BK0028","LU2289578879.USD","LU2328871848.SGD","LU2097828557.USD","LU0359201885.HKD","BK0183","LU1997245094.SGD"],"gpt_icon":0},{"id":"2619198064","title":"恒瑞醫藥(600276.SH)：1類創新藥海曲泊帕乙醇胺片新增適應症","url":"https://stock-news.laohu8.com/highlight/detail?id=2619198064","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619198064?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 17:43","pubTimestamp":1773395002,"startTime":"0","endTime":"0","summary":"智通财经APP讯，恒瑞医药(600276.SH)发布公告，近日，公司收到国家药品监督管理局的通知，批准公司自主研发的1类创新药海曲泊帕乙醇胺片新增适应症。批准的适应症：本品联合免疫抑制治疗适用于15岁及以上初治重型再生障碍性贫血(SAA)患者。海曲泊帕乙醇胺片于2021年获批上市两个适应症：1.本品适用于既往对糖皮质激素、免疫球蛋白等治疗反应不佳的慢性原发免疫性血小板减少症(ITP)成人患者。2.本品适用于对免疫抑制治疗(IST)疗效不佳的重型再生障碍性贫血(SAA)成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413668.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1820825898.SGD","BK0188","LU2148510915.USD","LU1064130708.USD","159992","BK0028","LU1023057109.AUD","LU1064131003.USD","LU1255011170.USD","LU2495084118.USD","LU2488822045.USD","LU2543165471.USD","BK0183","BK0060","LU1969619763.USD","LU1655091616.SGD","01276","LU1997244956.HKD","BK1574","LU2289578879.USD","LU2097828631.EUR","LU1997245177.USD","LU2097828805.USD","LU1781817850.SGD","06978","LU1328615791.USD","LU2580892789.USD","BK0196","LU0359201885.HKD","LU1146622755.USD","LU2097828474.EUR","LU2097828714.EUR","LU2097828557.USD","LU1997245094.SGD","600276","LU2580892862.HKD","BK0239","BK1161","LU1580142542.USD","LU0405327494.USD","LU0405327148.USD","LU2328871848.SGD","BK0012","BK1191","LU0359201612.USD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2619719872","title":"恒瑞醫藥：鹽酸伊立替康脂質體注射液（Ⅱ）臨床試驗獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2619719872","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619719872?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 17:39","pubTimestamp":1773394798,"startTime":"0","endTime":"0","summary":"人民财讯3月13日电，恒瑞医药(600276)3月13日公告，近日，子公司上海恒瑞医药有限公司收到国家药品监督管理局核准签发关于盐酸伊立替康脂质体注射液（Ⅱ）的《药物临床试验批准通知书》，将于近期开展临床试验。经查询，伊立替康相关剂型2024年全球总销售额约为3.73亿美元。截至目前，盐酸伊立替康脂质体注射液相关项目累计研发投入约为4.25亿元（未经审计）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603133671603794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1820825898.SGD","LU1255011170.USD","BK0239","BK0028","LU2580892862.HKD","BK0060","LU1969619763.USD","LU1328615791.USD","LU1064131003.USD","LU1655091616.SGD","LU1997245094.SGD","LU2097828714.EUR","LU2543165471.USD","BK0196","LU1997244956.HKD","BK0183","BK0188","BK0012","LU0359202008.SGD","LU2097828557.USD","LU2148510915.USD","LU1580142542.USD","LU2097828474.EUR","LU1023057109.AUD","LU2328871848.SGD","LU2488822045.USD","LU0359201885.HKD","BK1191","600276","LU0359201612.USD","LU0405327494.USD","LU1146622755.USD","LU1781817850.SGD","LU1997245177.USD","LU2580892789.USD","01276","LU2289578879.USD","LU2097828805.USD","LU2097828631.EUR","LU0405327148.USD","LU2495084118.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2619987211","title":"恒瑞醫藥：舒地胰島素諾利糖肽注射液上市許可申請獲國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2619987211","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619987211?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 17:39","pubTimestamp":1773394783,"startTime":"0","endTime":"0","summary":"每经AI快讯，3月13日，恒瑞医药(600276.SH)公告称，公司收到国家药监局下发的《受理通知书》，公司舒地胰岛素诺利糖肽注射液的上市许可申请获国家药监局受理。该药品适用于血糖控制不佳的成人2型糖尿病患者，在饮食和运动基础上联合其他口服降糖药物，改善血糖控制。该药品是公司自主研发的由长效基础胰岛素类似物和胰高血糖素样肽-1受体激动剂组成的固定比例复方制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603133671602785.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603133671602785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","BK0239","LU1023057109.AUD","LU1997245094.SGD","LU2097828714.EUR","LU1580142542.USD","LU2488822045.USD","LU2580892789.USD","LU1064130708.USD","BK0196","BK0183","LU2543165471.USD","01276","LU0359202008.SGD","LU0359201885.HKD","LU2097828805.USD","LU2495084118.USD","LU1064131003.USD","LU1328615791.USD","LU1655091616.SGD","LU1969619763.USD","600276","BK0060","LU2148510915.USD","LU1997245177.USD","BK0028","LU2580892862.HKD","LU1997244956.HKD","LU1255011170.USD","LU0405327148.USD","LU2097828474.EUR","LU0405327494.USD","BK0012","LU1820825898.SGD","LU0359201612.USD","LU2289578879.USD","LU1781817850.SGD","LU2097828557.USD","LU1146622755.USD","LU2097828631.EUR","LU2328871848.SGD","BK0188"],"gpt_icon":0},{"id":"2619610511","title":"創新賽道升温，恒瑞、百濟等藥企集體加碼研發","url":"https://stock-news.laohu8.com/highlight/detail?id=2619610511","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619610511?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 15:52","pubTimestamp":1773388350,"startTime":"0","endTime":"0","summary":"值得一提的是，在此背景下，恒瑞、百济等大批药企都表示将持续加大研发，聚焦GLP1、肿瘤、ADC、AI 制药等核心赛道。2月26日，百济神州发布2025年度业绩快报公告。据了解，近年来百济神州研发投入呈持续增长态势，2024年单年研发支出达141.4亿元，2025年全年研发费用为约合人民币154.5亿元，同比增长10%。根据季报公布的数字计算，恒瑞医药累计研发投入已超500亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313155524a4661da4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313155524a4661da4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU0359202008.SGD","BK1191","BK1574","LU1023057109.AUD","LU2543165471.USD","01276","LU0359201885.HKD","BK1161","06978"],"gpt_icon":0},{"id":"2619616103","title":"世界腎臟日：全球219款腎病藥上市！金賽藥業BCMA新藥與恒瑞醫藥SGLT2/GLP-1管線競速","url":"https://stock-news.laohu8.com/highlight/detail?id=2619616103","media":"摩熵医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619616103?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 12:28","pubTimestamp":1773376095,"startTime":"0","endTime":"0","summary":"截至2025年的最新评估，全球CKD患者总数约为8.5亿，其中高达90%的个体尚未知晓自身病情。该研究是全球首个在糖尿病肾病人群中完成概念性验证的口服小分子GLP-1受体激动剂，有望为患者提供更便捷的治疗选择。世界肾脏日的年度呼吁不应仅停留于口号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313122912954b8117&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313122912954b8117&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","LU1023057109.AUD","BK1191","LU0359202008.SGD","LU2543165471.USD","01276","LU0359201612.USD"],"gpt_icon":0},{"id":"2619161081","title":"「十五五」開局，恒瑞醫藥將站在新起點加速推進醫藥創新","url":"https://stock-news.laohu8.com/highlight/detail?id=2619161081","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619161081?lang=zh_tw&edition=fundamental","pubTime":"2026-03-13 10:23","pubTimestamp":1773368583,"startTime":"0","endTime":"0","summary":"2026年是“十五五”开局之年，站在新起点，恒瑞医药将紧扣\"十五五\"规划纲要要求，加速推进医药创新。作为国内大型药企，恒瑞医药以创新转型为核心引擎，已构建起以自主原研为驱动的产品与技术体系，公司已有20多款1类创新药获批上市。在肿瘤方面，恒瑞医药形成覆盖七大高发癌种、肿瘤支持治疗及多个重大未满足临床需求领域的系统化布局。如2025年上半年，恒瑞医药创新药销售及许可收入占比突破60%，占公司营业收入比重60.66%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031310252197b06142&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031310252197b06142&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","01276","BK1191","09939","BK1574","LU0359201885.HKD","LU0359202008.SGD","LU1023057109.AUD","LU0359201612.USD","BK1515","BK1161"],"gpt_icon":0},{"id":"2618902170","title":"世界腎臟日｜警惕「沉默殺手」，藥企競速「護腎」","url":"https://stock-news.laohu8.com/highlight/detail?id=2618902170","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618902170?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 12:03","pubTimestamp":1773288195,"startTime":"0","endTime":"0","summary":"今年3月12日迎来第21个世界肾脏日，主题为“人人享有肾脏健康：关爱生命，守护地球”，强调个体健康与环境保护的双重关注。更值得警惕的是，CKD起病隐匿，早期常无明显症状，被称为“沉默的杀手”。此外，通过肾脏B超检查，能够观察肾脏形态和结构，排查囊肿、结石等问题。在此背景下，国内外药企加速布局肾病赛道。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312120402a6b9b780&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312120402a6b9b780&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","01276","BK1191","LU0359202008.SGD","LU0359201612.USD","LU1023057109.AUD","03692","LU2543165471.USD"],"gpt_icon":0},{"id":"2618902199","title":"14億歐元BD終止！恒瑞被默克\"退貨\"的背後……","url":"https://stock-news.laohu8.com/highlight/detail?id=2618902199","media":"药渡","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618902199?lang=zh_tw&edition=fundamental","pubTime":"2026-03-12 07:31","pubTimestamp":1773271895,"startTime":"0","endTime":"0","summary":"根据协议条款，恒瑞可获得总计高达14亿欧元的首付款、里程碑付款及销售分成，其中首付款1.6亿欧元在协议生效后即落入恒瑞囊中。02终止是“瘦身计划”一环默克此次终止合作的决策，并非针对恒瑞单一个案。值得注意的是，尽管合作终止，但合同并未约定退款条款。从更宏观的视角看，此次终止合作是默克战略调整的必然结果。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312073613a4623b0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312073613a4623b0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU0359201885.HKD","LU0359202008.SGD","BK1191","01276","LU2543165471.USD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2618407549","title":"穩字當頭：恒瑞醫藥換屆稍欠鋭氣","url":"https://stock-news.laohu8.com/highlight/detail?id=2618407549","media":"财中TMT","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618407549?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 18:58","pubTimestamp":1773226708,"startTime":"0","endTime":"0","summary":"3月3日，换届公告披露后的首个交易日，恒瑞医药A股收跌1.71%、港股收跌2.34%。2021年更成为恒瑞医药的大考年。这一年，恒瑞医药失去A股医药市值第一的荣耀。危急关头，已卸任近一年半的创始人孙飘扬，于2021年7月重返恒瑞医药，再度掌舵。财报数据显示，2025年三季度末，恒瑞医药合同负债余额从1.60亿元增至39.71亿元。2026年以来，截至目前，公开信息暂无恒瑞医药对外授权合作的新披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311194427a6b80d81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311194427a6b80d81&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU0359201885.HKD","LU1023057109.AUD","LU2543165471.USD","BK1191","LU0359202008.SGD","LU0359201612.USD"],"gpt_icon":0},{"id":"2618394021","title":"馮佶，恒瑞醫藥女總裁榮登2026「福布斯中國傑出商界女性100」排行榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2618394021","media":"北京药研汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618394021?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 17:55","pubTimestamp":1773222938,"startTime":"0","endTime":"0","summary":"刚刚，恒瑞医药官方发布，2026年3月9日，福布斯正式公布2026“中国杰出商界女性100”榜单，恒瑞医药总裁冯佶女士凭借其卓越的领导力与深厚的行业积淀，荣登2026年榜单，为“她力量”写下生动的时代注脚，也让更多人看见中国女性在医药创新领域持续生长的力量。冯佶，女，1970年出生，籍贯上海，现任恒瑞医药总裁兼首席运营官。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031121161297adc483&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031121161297adc483&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","01276","LU2543165471.USD","LU0359201885.HKD","BK1191","LU0359201612.USD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2618024919","title":"今日，康寧傑瑞官宣新CTO！來自恒瑞","url":"https://stock-news.laohu8.com/highlight/detail?id=2618024919","media":"药渡","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618024919?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 17:20","pubTimestamp":1773220800,"startTime":"0","endTime":"0","summary":"此次重磅人事任命，是康宁杰瑞在核心管理团队建设上的重要布局，恰逢公司从创新研发向商业化落地的关键节点。公告显示，其职业履历亮眼，在加入康宁杰瑞之前，职业生涯长期扎根江苏恒瑞医药及旗下子公司，逐步成长为生物药领域核心管理人才。王宏伟博士也对加入康宁杰瑞表达高度期待，他表示，康宁杰瑞作为行业内极具差异化创新能力与高成长潜力的生物制药公司，在双抗及ADC领域的战略布局和快速推进令其印象深刻。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117471097ad7b04&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117471097ad7b04&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201885.HKD","01276","BK1191","LU0359201612.USD","LU1023057109.AUD","LU0359202008.SGD","LU2543165471.USD"],"gpt_icon":0},{"id":"2618940731","title":"恒瑞醫藥海外大單告吹","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940731","media":"股市动态分析","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940731?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 17:13","pubTimestamp":1773220389,"startTime":"0","endTime":"0","summary":"大单告吹2023年10月30日，恒瑞医药与德国默克达成一项战略授权协议。HRS-1167片为恒瑞医药自主研发的PARP1小分子抑制剂，属于第二代PARP抑制剂，可治疗多种肿瘤疾病，首选适应症为前列腺癌。近日，默克宣布终止与恒瑞医药围绕PARP1抑制剂HRS-1167的全球授权合作。幸运的是，虽然大单告吹，但1.6亿欧元的首付款在2023年交易交割时已全额到账，且协议中无任何首付款退款条款，这笔钱恒瑞医药无需返还。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117195595486399&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031117195595486399&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1023057109.AUD","LU2543165471.USD","BK1191","LU0359201885.HKD","LU0359202008.SGD","LU0359201612.USD","01276"],"gpt_icon":0},{"id":"2618675910","title":"恒瑞醫藥：注射用SHR-9803獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2618675910","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618675910?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 17:07","pubTimestamp":1773220033,"startTime":"0","endTime":"0","summary":"【恒瑞医药：注射用SHR-9803获临床试验批准】恒瑞医药公告，注射用SHR-9803收到国家药品监督管理局签发的《药物临床试验批准通知书》（受理号：CXSL2501078），同意本品联合阿得贝利单抗±贝伐珠单抗±化疗在晚期恶性实体瘤患者中开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603113668861077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2488822045.USD","BK0012","LU2495084118.USD","LU0405327148.USD","LU1820825898.SGD","LU1997245177.USD","LU2580892862.HKD","LU2148510915.USD","BK0183","01276","BK0060","LU2289578879.USD","600276","LU1580142542.USD","LU2543165471.USD","LU2580892789.USD","LU2097828474.EUR","LU2097828631.EUR","LU0359202008.SGD","LU2328871848.SGD","LU1997244956.HKD","LU2097828557.USD","LU1655091616.SGD","LU1969619763.USD","BK0239","LU0405327494.USD","BK0188","LU1781817850.SGD","LU1997245094.SGD","BK0028","LU0359201612.USD","BK1191","LU1064131003.USD","BK0196","LU0359201885.HKD","LU1023057109.AUD","LU1328615791.USD","LU2097828805.USD","LU1146622755.USD","LU2097828714.EUR","LU1255011170.USD","LU1064130708.USD"],"gpt_icon":0},{"id":"2618940735","title":"恒瑞醫藥：董事會會議通告","url":"https://stock-news.laohu8.com/highlight/detail?id=2618940735","media":"香港交易所","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618940735?lang=zh_tw&edition=fundamental","pubTime":"2026-03-11 16:30","pubTimestamp":1773217842,"startTime":"0","endTime":"0","summary":"恒瑞医药于2026年3月11日宣布，将于2026年3月25日（星期三）召开董事会会议，主要议程包括审议及批准公司及其附属公司截至2025年12月31日止年度之全年业绩，并考虑派发末期股息事宜。会议将由董事长孙飘扬先生主持，出席会议的董事会成员包括6名执行董事、1名非执行董事及4名独立非执行董事。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031118411497ad8f50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026031118411497ad8f50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","LU0359202008.SGD","BK1191","LU2543165471.USD","LU1023057109.AUD","LU0359201885.HKD","LU0359201612.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}